Cancer Care Adds Ovarian Cancer Section to Website

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

NEW YORK--Cancer Care, Inc. has launched a new online resource for ovarian cancer patients and their families and friends. A new section added to Cancer Care’s website (www.cancercare.org) offers a comprehensive overview of ovarian cancer and a resource guide.

The new addition to the website is made possible through an educational grant from SmithKline Beecham Oncology. The ovarian cancer section complements Cancer Care’s other website sections on specific types of cancer such as breast, prostate, lung, colon, brain, and melanoma.

Information provided about the disease includes tumor differentiation and staging, risk factors, coping, and diagnostic and treatment options. Answers to common questions about ovarian cancer are also included.

"We wanted ovarian cancer patients to be able to address any technical or practical concerns they have regarding the disease," said Diane Blum, MSW, executive director of Cancer Care. "This website section, as with all of Cancer Care’s website sections, encourages patients to utilize all available resources for their medical, emotional, and financial needs. We believe it will help connect patients with essential resources."

Recent Videos
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Related Content